INTS · Intensity Therapeutics, Inc. · Executive Compensation
$4.04
+0.02 (+0.50%)
At close · Sep 10
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the cash and cash equivalents as of June 30, 2026, the Company's ability to continue its operations thereafter is dependent on obtaining additional capital, which is not within the Company's control. As a result, the Company believes there is substantial doubt about its ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Market Cap
$13.19M
Shares
3.26M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Lewis H. Bender | President and Chief Executive Officer | $1,355,482 |
| Joseph Talamo | Chief Financial Officer | $723,739 |
| John Wesolowski | Principal Accounting Officer and Controller | $378,452 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Lewis H. Bender | President and Chief Executive Officer | $2,486,169 |
| Joseph Talamo | Chief Financial Officer | $1,662,576 |
| John Wesolowski | Principal Accounting Officer and Controller | $569,129 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Lewis H. Bender | President and Chief Executive Officer | $1,235,740 |
| John Wesolowski | Principal Accounting Officer and Controller | $527,291 |
| Joseph Talamo | Chief Financial Officer | $456,371 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Lewis H. Bender | President and Chief Executive Officer | $994,571 |
| John Wesolowski | Principal Accounting Officer and Controller | $251,157 |
| Joseph Talamo | Chief Financial Officer | — |
Key facts
CIK
1567264
CUSIP
45828J202
13F (30d)
11 filings
10 filers
Visit website
Investor relations